Estimate-beating fourth-quarter earnings for Amgen Inc. pushed company shares about $7.95 higher to close at $167.53 on Friday as sales of its cholesterol treatment Repatha (evolocumab) rose and a closely watched phase III trial suggested that combining the antibody with optimized statin treatment could reduce the risk of heart attack and other CV events in patients with arterial plaque buildups.